Skip to main content
Top
Published in: Breast Cancer Research 1/2003

Open Access 01-02-2003 | Research article

Interleukin-2 and its receptor complex (α, β and γ chains) in in situand infiltrative human breast cancer: an immunohistochemical comparative study

Authors: Ignacio García-Tuñón, Mónica Ricote, Antonio Ruiz, Benito Fraile, Ricardo Paniagua, Mar Royuela

Published in: Breast Cancer Research | Issue 1/2003

Login to get access

Abstract

Introduction

The presence and distribution of interleukin-2 (IL-2) and its receptor complex (Rα, Rβ, Rγ) were studied in 52 women who were clinically and histopathologically diagnosed with breast tumours (17 in situ and 35 infiltrating), and in 13 women with benign fibrocystic lesions in the breast.

Methods

Immunohistochemistry with antibodies against IL-2, IL-2Rα, IL-2Rβ and IL-2Rγ was used. A comparative semiquantitative immunohistochemical study between the three breast groups (fibrocystic lesions, in situ tumours and infiltrating tumours) was performed.

Results

IL-2 and its three receptor chains were immunodetected in the cytoplasm of epithelial cells. The three receptor chains were also detected on the cell surface. In fibrocystic lesions, immunoreactions to IL-2 (38.5% of cases), IL-2Rα (53.8%) and IL-2Rβ (30.8%) were very weak, whereas immunoreaction to IL-2Rγ (46.1%) was somewhat more intense. In in situ tumours, the percentages of cases that immunostained positively for IL-2 and its three receptor chains were similar to those observed in fibrocystic lesions, but immunostainings of the four antibodies were more intense. In infiltrative tumours, the percentages of positively stained cases and also immunostaining intensities were approximately twice that found for in situ tumours. Within infiltrating tumours, the percentage of cases showing immunoreaction to IL-2 and their three receptor chains was higher in the patients with lymph node infiltration at the time of surgery.

Conclusion

The development of breast tumour is associated with an increased expression of IL-2 and its three receptor chains, and this expression also seems to be associated with the malignancy of the tumour.
Appendix
Available only for authorised users
Literature
1.
go back to reference Minami Y, Kono T, Miyazaki T, Tiguchi T: The IL-2 receptor complex: its structure, function and target genes. Annu Rev Immunol. 1993, 11: 245-267. 10.1146/annurev.iy.11.040193.001333.CrossRefPubMed Minami Y, Kono T, Miyazaki T, Tiguchi T: The IL-2 receptor complex: its structure, function and target genes. Annu Rev Immunol. 1993, 11: 245-267. 10.1146/annurev.iy.11.040193.001333.CrossRefPubMed
2.
go back to reference Whiteside TL, Herberman RB: The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol. 1995, 7: 704-710. 10.1016/0952-7915(95)80080-8.CrossRefPubMed Whiteside TL, Herberman RB: The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol. 1995, 7: 704-710. 10.1016/0952-7915(95)80080-8.CrossRefPubMed
3.
go back to reference Takeshita T, Aso H, Ahtani K, Ishii N, Kumaki S, Tanaka N, Munakata H, Nakamura M, Sugamura K: Cloning the gamma chain of the human IL-2 receptor. Science. 1992, 257: 379-382.CrossRefPubMed Takeshita T, Aso H, Ahtani K, Ishii N, Kumaki S, Tanaka N, Munakata H, Nakamura M, Sugamura K: Cloning the gamma chain of the human IL-2 receptor. Science. 1992, 257: 379-382.CrossRefPubMed
4.
go back to reference Robb RJ, Rusk CM, Yodoi J, Greene WC: Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high affinity receptors. Immunology. 1987, 84: 1987-2002. Robb RJ, Rusk CM, Yodoi J, Greene WC: Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high affinity receptors. Immunology. 1987, 84: 1987-2002.
5.
go back to reference Hatakeyama M, Tsudo M, Miramoto S, Kono T, Doi T, Miyata T, Miyasaka M, Taniguchi T: Interleukin 2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNAs. Science. 1989, 244: 551-556.CrossRefPubMed Hatakeyama M, Tsudo M, Miramoto S, Kono T, Doi T, Miyata T, Miyasaka M, Taniguchi T: Interleukin 2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNAs. Science. 1989, 244: 551-556.CrossRefPubMed
6.
go back to reference Arima N, Kamio M, Okuma M, Ju G, Uchiyama T: The IL-2 receptor alpha-chain alters the binding of IL-2 to the beta-chain. J Immunol. 1991, 147: 3396-3401.PubMed Arima N, Kamio M, Okuma M, Ju G, Uchiyama T: The IL-2 receptor alpha-chain alters the binding of IL-2 to the beta-chain. J Immunol. 1991, 147: 3396-3401.PubMed
7.
go back to reference Azzarone B, Pottin-Clemenceasu C, Krief P, Rubinstein E, Jasmin C, Scudeletti M, Indiveri F: Are interleukin-2 and interleukin-15 tumor promoting factors for human non-hematopoietic cells?. Eur Cytokine Netw. 1996, 7: 27-36.PubMed Azzarone B, Pottin-Clemenceasu C, Krief P, Rubinstein E, Jasmin C, Scudeletti M, Indiveri F: Are interleukin-2 and interleukin-15 tumor promoting factors for human non-hematopoietic cells?. Eur Cytokine Netw. 1996, 7: 27-36.PubMed
8.
go back to reference Lin WC, Yasumura S, Suminami Y, Sung MW, Nagashima S, Stanson J, Whiteside TL: Constitutive production of IL-2 by human carcinoma cells, expression of IL-2 receptor, and tumor cell growth. J Immunol. 1995, 155: 4805-4816.PubMed Lin WC, Yasumura S, Suminami Y, Sung MW, Nagashima S, Stanson J, Whiteside TL: Constitutive production of IL-2 by human carcinoma cells, expression of IL-2 receptor, and tumor cell growth. J Immunol. 1995, 155: 4805-4816.PubMed
9.
go back to reference Reichert T, Watkins S, Stanson J, Johnson JT, Whiteside TL: Endogenous IL-2 in cancer cells: a marker of cellular proliferation. J Histochem Cytochem. 1998, 46: 603-611.CrossRefPubMed Reichert T, Watkins S, Stanson J, Johnson JT, Whiteside TL: Endogenous IL-2 in cancer cells: a marker of cellular proliferation. J Histochem Cytochem. 1998, 46: 603-611.CrossRefPubMed
10.
go back to reference Ridings J, Macardle PJ, Virad RW, Byard RW, Skinner J, Zola H: Cytokine receptor by solid tumours. Therapeut Immunol. 1995, 2: 67-76. Ridings J, Macardle PJ, Virad RW, Byard RW, Skinner J, Zola H: Cytokine receptor by solid tumours. Therapeut Immunol. 1995, 2: 67-76.
11.
go back to reference Royuela M, De Miguel MP, Bethencourt FR, Fraile B, Arenas MI, Paniagua R: IL-2, its receptors, and bcl-2 and bax genes in normal, hyperplastic and carcinomatous human prostates: immunohistochemical comparative analysis. Growth Factors. 2000, 18: 135-146.CrossRefPubMed Royuela M, De Miguel MP, Bethencourt FR, Fraile B, Arenas MI, Paniagua R: IL-2, its receptors, and bcl-2 and bax genes in normal, hyperplastic and carcinomatous human prostates: immunohistochemical comparative analysis. Growth Factors. 2000, 18: 135-146.CrossRefPubMed
12.
go back to reference Reichert T, Kashii Y, Stanson J, Whiteside TL: The role of endogenous interleukin-2 in proliferation of human carcinoma cell lines. Br J Cancer. 1999, 81: 822-831. 10.1038/sj.bjc.6690770.CrossRefPubMedPubMedCentral Reichert T, Kashii Y, Stanson J, Whiteside TL: The role of endogenous interleukin-2 in proliferation of human carcinoma cell lines. Br J Cancer. 1999, 81: 822-831. 10.1038/sj.bjc.6690770.CrossRefPubMedPubMedCentral
13.
go back to reference Wigginton JM, Komschlies KL, Back TC, Franco JL, Brunda MJ, Wiltrou RH: Administration of interleukin 12 and pulse interleukin 2 and rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst. 1996, 88: 38-43.CrossRefPubMed Wigginton JM, Komschlies KL, Back TC, Franco JL, Brunda MJ, Wiltrou RH: Administration of interleukin 12 and pulse interleukin 2 and rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst. 1996, 88: 38-43.CrossRefPubMed
14.
go back to reference Wigginton JM, Park J, Gruys ME, Young HA, Jorcyk CL, Back TC, Brunda MJ, Strieter RM, Ward J, Green JE, Wiltrou RH: Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, fas/fas ligand gene expression, and mammary epithelial apoptosis. J Immunol. 2001, 166: 1156-1168.CrossRefPubMed Wigginton JM, Park J, Gruys ME, Young HA, Jorcyk CL, Back TC, Brunda MJ, Strieter RM, Ward J, Green JE, Wiltrou RH: Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, fas/fas ligand gene expression, and mammary epithelial apoptosis. J Immunol. 2001, 166: 1156-1168.CrossRefPubMed
15.
go back to reference Reichert T, Nagashima S, Kashii Y, Stanson J, Gao G, Dou QP, Whiteside TH: Interleukin-2 expression in human carcinomas cell lines and its role in cell cycle progression. Oncogene. 2000, 19: 514-525. 10.1038/sj.onc.1203391.CrossRefPubMed Reichert T, Nagashima S, Kashii Y, Stanson J, Gao G, Dou QP, Whiteside TH: Interleukin-2 expression in human carcinomas cell lines and its role in cell cycle progression. Oncogene. 2000, 19: 514-525. 10.1038/sj.onc.1203391.CrossRefPubMed
16.
go back to reference Katano M, Matsuo T, Morisaki T, Naito K, Nagumo F, Kubota E, Nakamura M, Hisatsugu T, Tadano J: Increased proliferation of human breast carcinoma cell line by recombinant interleukin-2. Cancer Immunol Immunother. 1994, 39: 161-166. 10.1007/s002620050108.CrossRefPubMed Katano M, Matsuo T, Morisaki T, Naito K, Nagumo F, Kubota E, Nakamura M, Hisatsugu T, Tadano J: Increased proliferation of human breast carcinoma cell line by recombinant interleukin-2. Cancer Immunol Immunother. 1994, 39: 161-166. 10.1007/s002620050108.CrossRefPubMed
17.
go back to reference Carloni G, Paterson H, Mareel M, Augery-Bourget Y, Sahraoui Y, Rubinstein E, Suarez H, Azzarone B: N-ras dependent revertant phenotype in human HT 1080 fibrosarcoma cells is associated with loss of proliferation within normal tissues and expression of adult membrane antigen phenotypes. Oncogene. 1989, 4: 873-880.PubMed Carloni G, Paterson H, Mareel M, Augery-Bourget Y, Sahraoui Y, Rubinstein E, Suarez H, Azzarone B: N-ras dependent revertant phenotype in human HT 1080 fibrosarcoma cells is associated with loss of proliferation within normal tissues and expression of adult membrane antigen phenotypes. Oncogene. 1989, 4: 873-880.PubMed
18.
go back to reference Plaisance S, Rubinstein E, Alileche A, Sahraoui Y, Krief P, Aurgery-Bourget Y, Jaomin C, Suarez H, Azzarone B: Expression of the interleukin-2 receptor in human fibroblasts and its biological significance. Int Immunol. 1992, 4: 739-746.CrossRefPubMed Plaisance S, Rubinstein E, Alileche A, Sahraoui Y, Krief P, Aurgery-Bourget Y, Jaomin C, Suarez H, Azzarone B: Expression of the interleukin-2 receptor in human fibroblasts and its biological significance. Int Immunol. 1992, 4: 739-746.CrossRefPubMed
19.
go back to reference Sander B, Anderson J, Anderson U: Assessment of cytokines by immunofluorescence and the paraformaldehyde-saponin procedure. Immunol Rev. 1991, 119: 65-93.CrossRefPubMed Sander B, Anderson J, Anderson U: Assessment of cytokines by immunofluorescence and the paraformaldehyde-saponin procedure. Immunol Rev. 1991, 119: 65-93.CrossRefPubMed
20.
go back to reference Ellery JM, Nicholls PJ: Alternate signalling pathways from interleukin-2 receptor. Cytokine Growth Factor Rev. 2002, 13: 27-40. 10.1016/S1359-6101(01)00023-5.CrossRefPubMed Ellery JM, Nicholls PJ: Alternate signalling pathways from interleukin-2 receptor. Cytokine Growth Factor Rev. 2002, 13: 27-40. 10.1016/S1359-6101(01)00023-5.CrossRefPubMed
21.
go back to reference Graffen SL, Lai SY, Xu W, Gouilleux F, Groner B, Goldsmith MA, Greene WC: Signalling through the interleukin-2 receptor β chain activates a stat-5-like DNA-binding activity. Proc Natl Acad Sci USA. 1995, 92: 7192-7196.CrossRef Graffen SL, Lai SY, Xu W, Gouilleux F, Groner B, Goldsmith MA, Greene WC: Signalling through the interleukin-2 receptor β chain activates a stat-5-like DNA-binding activity. Proc Natl Acad Sci USA. 1995, 92: 7192-7196.CrossRef
22.
go back to reference Lelle RJ: In situ determination of the Ki-67 growth fraction (Ki-67GF) in human tumors (studies in breast cancer). Acta Histochem Suppl. 1990, 39: 109-1024.PubMed Lelle RJ: In situ determination of the Ki-67 growth fraction (Ki-67GF) in human tumors (studies in breast cancer). Acta Histochem Suppl. 1990, 39: 109-1024.PubMed
23.
go back to reference Tavassoli FA: Infiltrating carcinomas, common and familiar special types. In: Pathology of the Breast. Edited by: Appleton and Lange. 1992, Connecticut, 293-333. Tavassoli FA: Infiltrating carcinomas, common and familiar special types. In: Pathology of the Breast. Edited by: Appleton and Lange. 1992, Connecticut, 293-333.
24.
go back to reference Querzoli P, Albonico G, Ferreti S, Rinaldi R, Magri E, Nenci I: Quantitative immunoprofiles of breast cancer performed by image analysis. Anal Quant Cytol Histol. 1999, 21: 151-160.PubMed Querzoli P, Albonico G, Ferreti S, Rinaldi R, Magri E, Nenci I: Quantitative immunoprofiles of breast cancer performed by image analysis. Anal Quant Cytol Histol. 1999, 21: 151-160.PubMed
25.
go back to reference Bich-Thuy LT, Bukovich M, Peffer NJ, Fauci AS, Kehrl JH, Greene WC: Direct activation lf human resting T cells by IL-2: the role of an IL-2 receptor distinct from the TAC protein. J Immunol. 1987, 139: 1550-1556.PubMed Bich-Thuy LT, Bukovich M, Peffer NJ, Fauci AS, Kehrl JH, Greene WC: Direct activation lf human resting T cells by IL-2: the role of an IL-2 receptor distinct from the TAC protein. J Immunol. 1987, 139: 1550-1556.PubMed
26.
go back to reference Russell SM, Keegan AD, Harada N, Nakamura Y, Noguchi M, Leland P, Friedman MC, Millajima A, Puri RQ, Paul WE, Leonard WJ: Interleukin-2 receptor. Science. 1993, 262: 1880-1883.CrossRefPubMed Russell SM, Keegan AD, Harada N, Nakamura Y, Noguchi M, Leland P, Friedman MC, Millajima A, Puri RQ, Paul WE, Leonard WJ: Interleukin-2 receptor. Science. 1993, 262: 1880-1883.CrossRefPubMed
27.
go back to reference Kondo M, Takesita T, Ishii N, Nakamura M, Watanabe S, Arai K, Sugamura K: Sharing of interleukin-2 (IL-2) receptor γ chain between receptors for IL-2 and IL-4. Science. 1993, 262: 1874-1877.CrossRefPubMed Kondo M, Takesita T, Ishii N, Nakamura M, Watanabe S, Arai K, Sugamura K: Sharing of interleukin-2 (IL-2) receptor γ chain between receptors for IL-2 and IL-4. Science. 1993, 262: 1874-1877.CrossRefPubMed
28.
go back to reference Cosenza L, Gorgun G, Urbano A, Foss F: Interleukin-7 receptor and activation in nonhaematopoietic neoplasic cell lines. Cell Signal. 2002, 14: 317-325. 10.1016/S0898-6568(01)00245-5.CrossRefPubMed Cosenza L, Gorgun G, Urbano A, Foss F: Interleukin-7 receptor and activation in nonhaematopoietic neoplasic cell lines. Cell Signal. 2002, 14: 317-325. 10.1016/S0898-6568(01)00245-5.CrossRefPubMed
29.
go back to reference Maeurer MJ, Walter W, Martin D, Zytyogel L, Elder E, Storkus W, Lotze MT: Interleukin-7 (IL-7) is produced by tissues from colorectal cancer and promotes preferential expansion of tumour infiltrating lymphocytes. Scand J Immunol. 1997, 42: 182-192. 10.1046/j.1365-3083.1997.d01-384.x.CrossRef Maeurer MJ, Walter W, Martin D, Zytyogel L, Elder E, Storkus W, Lotze MT: Interleukin-7 (IL-7) is produced by tissues from colorectal cancer and promotes preferential expansion of tumour infiltrating lymphocytes. Scand J Immunol. 1997, 42: 182-192. 10.1046/j.1365-3083.1997.d01-384.x.CrossRef
30.
go back to reference Smith KA: The interleukin-2 receptor. Annu Rev Cell Biol. 1989, 5: 397-425. 10.1146/annurev.cb.05.110189.002145.CrossRefPubMed Smith KA: The interleukin-2 receptor. Annu Rev Cell Biol. 1989, 5: 397-425. 10.1146/annurev.cb.05.110189.002145.CrossRefPubMed
Metadata
Title
Interleukin-2 and its receptor complex (α, β and γ chains) in in situand infiltrative human breast cancer: an immunohistochemical comparative study
Authors
Ignacio García-Tuñón
Mónica Ricote
Antonio Ruiz
Benito Fraile
Ricardo Paniagua
Mar Royuela
Publication date
01-02-2003
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2003
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr730

Other articles of this Issue 1/2003

Breast Cancer Research 1/2003 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine